Curatis Holding AG: Business Overview, Financials & Competitive Analysis
Curatis Holding AG scores 6/10 on the AskCyborg Cyborg Score (Solid). Rare disease focus with proven distribution revenue combined with clinical-stage assets offers asymmetric risk-reward, contingent on capital deployment and regulatory success. Curatis demonstrates strong operational fundamentals in orphan drug distribution with documented 30% growth in 2024. However, the company faces capital constraints (recent CHF 1.2M private placement indicates funding.
What is Curatis Holding AG's industry? Curatis Holding AG (curatis.com) operates in Specialty Pharmaceuticals - Orphan/Rare Diseases. AskCyborg classifies Curatis Holding AG under Specialty Pharmaceuticals - Orphan/Rare Diseases in its company registry.
Curatis Holding AG is a Swiss specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. Founded in 2002 and listed on SIX Swiss E...
Cyborg Score thesis
Rare disease focus with proven distribution revenue combined with clinical-stage assets offers asymmetric risk-reward, contingent...
Read the full analyst-debate transcript →Get the Latest Curatis Holding AG Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCuratis Holding AG Overview
Pro stress-test →Curatis Holding AG is a Swiss specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. Founded in 2002 and listed on SIX Swiss Exchange since early 2024, Curatis operates through both a profitable distribution business for orphan drugs and a pipeline of proprietary drug candidates in clinical development.
Strategic Profile
Pro stress-test →Curatis has differentiated itself as a leader in the Swiss orphan drug market with exclusive distribution rights for 40+ products and a growing presence planned across major European markets. The company combines immediate revenue generation from its distribution business with high-value development opportunities, particularly its Phase IIb lead candidate C-PTBE-01 for peritumoral brain edema. Recent financials show 30% distribution sales growth and a strategic pivot toward geographic and product portfolio expansion.
Competitive Landscape
Pro stress-test →Curatis competes in the niche orphan drug space against larger pharmaceutical distributors and integrated biotech companies. Direct competitors include Recordati (orphan drugs division), Santhera Pharmaceuticals, and Actelion (acquired by J&J). Unlike larger competitors, Curatis maintains focused positioning in Switzerland with European expansion ambitions, competing through specialized expertise and direct relationships rather than scale.
Industry Context
Curatis Holding AG operates in Specialty Pharmaceuticals - Orphan/Rare Diseases.
Key facts
Founded: 2002 · Headquarters: Liestal, Switzerland · Employees: ~8 · Revenue: CHF 6.9M (2024, 8-month post-acquisition) · Market cap: CHF 58.16M